PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Gross profit growth above 1.5x AXSM's 21.76%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-1.47%
Negative EBIT growth while AXSM is at 19.76%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.47%
Negative operating income growth while AXSM is at 19.76%. Joel Greenblatt would press for urgent turnaround measures.
-1.89%
Negative net income growth while AXSM stands at 18.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
2.63%
EPS growth under 50% of AXSM's 19.76%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
2.63%
Diluted EPS growth under 50% of AXSM's 19.76%. Michael Burry would worry about an eroding competitive position or excessive dilution.
3.22%
Share count expansion well above AXSM's 1.19%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
3.22%
Diluted share count expanding well above AXSM's 1.19%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Negative OCF growth while AXSM is at 38.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-50.21%
Negative FCF growth while AXSM is at 38.73%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AXSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.36%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
62.52%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
-48.56%
Negative 3Y OCF/share CAGR while AXSM stands at 45.54%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
94.18%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
69.28%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
-24.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-50.75%
Negative equity/share CAGR over 10 years while AXSM stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-32.62%
Negative 5Y equity/share growth while AXSM is at 874.27%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-67.01%
Negative 3Y equity/share growth while AXSM is at 70.22%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Negative asset growth while AXSM invests at 2.41%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
We’re deleveraging while AXSM stands at 0.26%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.75%
We increase R&D while AXSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-21.32%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.